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Management of endoleaks associated with
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Julio A. Rodriguez-Lopez, MD,b James Williams, BS,b Dawn Olsen, PA,b and Edward B. Diethrich, MD,b
Dover, Del; and Phoenix, Ariz
Objective: Endoluminal grafting is emerging as a less invasive alternative to the treatment of descending thoracic aorta
diseases. Endoleaks (continued pressurization of the treated aorta external to the endoluminal graft) are a potential
complication. We reviewed our cumulative endovascular experience for descending thoracic aorta pathologies with
respect to the management of endoleaks and associated patient outcomes.
Methods: As part of a single-site investigational device–exemption protocol, 249 patients (146 men, 103 women) with
thoracic aortic diseases underwent attempted delivery of a TAG endoprosthesis (W. L. Gore & Associates, Flagstaff, Ariz)
between February 2000 and August 2005. Indications for study enrollment included 111 atherosclerotic aneurysms
(44.6%), 67 aortic dissections (26.9%), 27 penetrating aortic ulcers (10.8%), 14 contained ruptures (5.6%), 11
pseudoaneurysms (4.4%), 9 acute aortic transections (3.6%), 7 aortobronchial fistulas (2.8%), 2 endoleaks (0.8%) after
prior thoracic endoluminal grafting, and 1 (0.4%) adult coarctation. Endoleak surveillance was performed using serial
computed tomography scans.
Results: Mean patient age was 68 years (range, 23-91 years). Endoleak developed in 38 patients (15.3%): 15 distal type I
(39.5%), 13 proximal type I (34.2%), 8 type II (21.1%) and 2 type III (5.3%). No surgical intervention was performed in
26 patients (68.4%), in which the endoleak spontaneously resolved in 14 (53.8%), 8 (30.8%) are being monitored and are
asymptomatic, 3 (11.5%) died of unrelated causes, 2 (7.7%) withdrew from the study, and 1 (3.8%) was lost to follow-up.
Twelve patients (31.6%) required reintervention using an additional endoluminal graft: 8 (66.7%) with a proximal type
I endoleak, 2 (16.7%) with a distal type I endoleak, 1 (8.3%) with both distal type I and type III endoleaks, and 1 (8.3%)
with a type III endoleak. Open conversions were necessary secondary to device deployment difficulties in two patients
(0.8%), and due to expansion of a thoracoabdominal aneurysm and rupture of an aneurysm secondary to a type II
endoleak in one patient (0.5%) each.
Conclusion: Endoleaks are an infrequent, yet important, complication after thoracic endografting. Many endoleaks will
resolve spontaneously, but some patients may require another endovascular intervention. Close surveillance is recom-
mended for these patients; however, open conversion is rarely indicated. Because more diseases of the thoracic aorta are
being treated using an endovascular approach, a standardized treatment algorithm is essential to safely and effectively
manage associated endoleaks. ( J Vasc Surg 2008;48:69-73.)An endoleak occurs when blood flows outside the stent
graft lumen and may complicate endovascular treatment of
abdominal and thoracic aortic disease by contributing to
enlargement or rupture of an aneurysm. Although there are
considerable data regarding endografting in the abdominal
aorta, the etiology of endoleaks remains controversial.1-4
The thoracic aortic stent graft is a relative newcomer for use
in endovascular intervention, and the anatomic and patho-
logic challenges in this vascular region differ from those in
the abdominal aorta. As yet, the precursors of endoleak
after thoracic aortic endovascular interventions are poorly
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endoleaks encountered during a single-center study and
describe their relationship to the pathologies treated.
METHODS
This report analyzes thoracic aortic endovascular repair
at our institution (Arizona Heart Institute) from February
2000 to August 2005, with special emphasis on endoleaks.
Indications for study enrollment included atherosclerotic
aneurysms, aortic dissections, penetrating aortic ulcers,
contained ruptures, pseudoaneurysms, acute aortic transec-
tions, aortobronchial fistulas, endoleaks after thoracic en-
doluminal grafting, and coarctation.
All patients were enrolled in a single-center investiga-
tional device–exemption protocol approved by an Institu-
tional Review Board. Before the procedure, patients signed
an informed consent for use of the TAG endoprosthesis
(W. L. Gore & Associates, Flagstaff, Ariz). Between Feb-
ruary 2000 and May 2001, patients received the original
TAG configuration with two longitudinal nitinol spines for
columnar support. The device manufacturer voluntarily
69
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investigate device fracture rates; a new version of the TAG
without longitudinal spines was introduced in February
2003 and used during the remainder of our study. Patient
demographics, associated comorbidities, clinical presenta-
tion, operative management, procedural details, complica-
tions, and reinterventions were monitored prospectively.
All procedures were performed in the operating endo-
vascular suite under general anesthesia. Serum levels of
blood-urea nitrogen and creatinine were evaluated before
scanning with contrast to assess the risk of dye administra-
tion. Digital subtraction angiography was obtained in all
the cases, and intravascular ultrasound was used to confirm
vessel measurements and examine aortic pathologies. After
TAG deployment, an angiogram was obtained. Before dis-
charge, high-resolution computed tomography (CT) scan-
ning was used to evaluate device performance and deter-
mine the presence of endoleaks.
Patients were offered treatment of endoleaks as follows:
type I proximal and distal endoleaks as well as type III
endoleaks were treated at the time of discovery. An excep-
tion was the case of type I distal endoleak in patients with
dissection in whom follow-up was performed, unless the
patient was symptomatic or a pseudoaneurysm had formed.
Type II endoleaks were monitored. CT scans of the chest
(with and without contrast) were done at 1, 6, and 12
months the first year, and annually thereafter. If an en-
doleak was discovered in follow-up, CT scanning was per-
formed every 3 months.
An endoleak was defined as the persistence of blood
flow outside the lumen of the endograft and within the
aneurysm sac or the adjacent vascular segment treated by
the graft.5,6 Endoleaks were classified into five categories
according to the time of occurrence relative to the operative
procedure and the site of origin.6
RESULTS
During a 5-year period, 249 patients underwent TAG
implantation. Demographics, indications for stent grafting,
and type of endoleaks and outcomes are described in Table I.
Type I distal endoleak. In 15 patients with type I
distal endoleaks, 13 had no intervention, and two had
further procedures (Table II).
Nonintervention group. In eight of the patients with
chronic dissections (with or without pseudoaneurysm for-
mation) in whom the distal endoleak was a result of persis-
tent perfusion of the false lumen from the distal re-entry
site, the endoleak spontaneously resolved in seven (1
month, n 6;1 year, n 1). An endoleak was seen in the
eighth dissection patient at 48 months. This patient re-
mains asymptomatic and is being monitored. In two pa-
tients with descending thoracic aortic aneurysms, en-
doleaks thought to be present immediately after the
procedure were not seen in follow-up scans before dis-
charge. In the patient with the aortobronchial fistula, a
distal endoleak was seen at 60 months; the patient remains
asymptomatic and is currently being monitored. One pa-tient was lost to follow-up, and one died unrelated to
endoleak.
Intervention group. Two patients with distal type I
endoleak required further reintervention. Both patients
had been treated for descending thoracic aortic aneurysms.
In one patient, an endoleak and an increase in aneurysm sac
size became apparent 6 months after the initial procedure,
and an intervention with two additional endoprostheses
was performed successfully. In the other patient, the distal
Table I. Demographics and results
Variable Value
Demographics, No. 249
Age, mean (range) years 68 (23-91)
Sex, No. (%)
Men 146 (58.6)
Women 103 (41.4)
Follow-up, mean  SD months (range) 20.0  19.4 (1-60)
Indications for TAG, No. (%)
Atherosclerotic aneurysms 111 (44.6)
Aortic dissections 67 (26.9)
Penetrating aortic ulcers 27 (10.8)
Contained ruptures 14 (5.6)
Pseudoaneurysms 11 (4.4)
Acute aortic transections 9 (3.6)
Aortobronchial fistulas 7 (2.8)
Endoleak 2 (0.8)
Coarctation 1 (0.4)
Type of endoleaks, No. (%) 58
Type I distal 15 (39.5)
Type I proximal 13 (34.2)
Type II 8 (21.1)
Type III 2 (0.5)
Type IV 0
Type V 0
Fate of endoleak, No. (%) 38
Spontaneously resolved 14 (36.8)
Required reintervention 12 (31.6)
Under surveillance 8 (2.3)
Type I proximal 5
Type I distal 2
Type II 1
Withdrew from study 2 (0.5)
Died (cause not related to endoleak) 1 (0.4)
Lost to follow-up 1 (0.4)
Table II. Outcome of type I distal endoleak in 15
patientsa
Indication
Intervention (outcome)
No Yes
Patients, No. 11 2
Chronic dissection 7 (resolved in 6)
Descending thoracic aneurysms 2 (resolved) 2
Chronic dissection with
pseudoaneurysm 1 (resolved)
Aortobronchial fistula with
distal dissection 1 (not resolved)
a1 patient was lost to follow-up and 1 died of a cause unrelated to the
endoleak (non-intervention group n  13).endoleak was seen during a 6-month follow-up exam as
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tant to undergo further surgery initially; however, 2
months later he had back pain and the aneurysm sac size
had increased, and he agreed to deployment of an addi-
tional TAG. This procedure was complicated by small iliac
artery size, vessel tortuosity, and prior common femoral
artery patch angioplasty. Ultimately, the TAG could not be
inserted. Balloon angioplasty was performed on the exist-
ing graft with coil embolization of the aneurysm sac. Two
days later, the patient presented with significant coagulopa-
thy and renal failure, and his family withdrew supportive
measures.
Type I proximal endoleak. Type I proximal en-
doleaks occurred in 13 patients; 4 had been treated for
chronic dissections, 7 for aneurysms, 1 for contained rup-
ture and pseudoaneurysm, and 1 for chronic dissection and
pseudoaneurysm (Table III).
Intervention group. Reintervention with an addi-
tional TAGor treatment with balloon angioplasty and coils,
or both, was performed in eight patients with type I prox-
imal endoleaks. In three patients with aneurysmal pathol-
ogy, proximal endoleaks were identified at 6, 22, and 37
months, respectively. The endoleak found at 6 months was
associated with proximal expansion of the aneurysm, and an
open procedure using aortic arch debranching and ante-
grade delivery of an additional TAG was performed. An
additional TAG was placed in each of the other two pa-
tients, and the endoleaks resolved. In the four patients with
chronic dissections, endoleaks at day 5 (n 1), at 3 months
(n  2), and at 16 months (n  1) after the primary
intervention were treated with an additional TAG. The
patient treated at 16 months also received coils to the left
subclavian artery. In the patient with chronic dissection and
pseudoaneurysm formation, a proximal endoleak was
treated at day 5 after the primary procedure with two
additional TAG devices and coverage of the left subclavian
artery.
No intervention. Five of the patients with a type I prox-
imal endoleaks had no further intervention; four had been
treated for aneurysms in the descending thoracic aorta and
one patient for contained rupture with pseudoaneurysm for-
mation. Despite our recommendations for further interven-
tion, all five refused additional procedures and are under
surveillance. Endoleaks were identified at 30 days in the pa-
Table III. Outcome of type I proximal endoleak in 13
patients
Indication
Intervention
(outcome)
No Yes
Patients, No. 5 8
Chronic dissection 4
Descending thoracic aneurysms 4 (not resolved) 3
Chronic dissection with pseudoaneurysm 1
Contained rupture with pseudoaneurysm 1 (not resolved)tient with the contained rupture and at 6 months (n 1) and48months (n 3) in the aneurysm patients. No expansion of
the aneurysm sac was seen in any of the cases.
Type II endoleaks. Type II endoleaks occurred in
eight patients (21%); seven had been treated for aneurysms
and one for chronic dissection. There were no reinterven-
tions (Table IV).
Three patients left the operating room with type II
endoleaks. One resolved 1 month, and two resolved 1
year. Three more endoleaks were identified at 6 months, 16
months, and 48months, respectively; the two discovered at
6 and 16 months resolved, and the later is being monitored
and shows no significant change 4 years after the proce-
dure. One endoleak was seen at 24 months, but the patient
died before additional follow-up of causes unrelated to the
endoleak. Another patient was lost to follow-up at 36
months.
Type III. Two type III endoleaks were identified, one
at 6 months in a patient with an existing distal type I
endoleak (diagnosed at 3 months) and the other at 1 year.
The patient with type I and III endoleaks was treated after
discovery of the type III leak and received an additional
TAG device and coils between the graft and the aneurysm
sac; both endoleaks resolved.
The patient with the solo type III endoleak was at high
risk for intervention because of comorbidities and was
reluctant to undergo further treatment; his aneurysm sac
was stable until 33 months, when an enlargement was seen.
An additional TAG was placed to line the inner lumen of
the previous graft site and bridge the separation. The
endoleak resolved, but a possible type II endoleak was seen
at 45 months at the level of T8-T9 at another facility. The
patient had a syncopal episode, and a rupture of the de-
scending aneurysm sac was suspected. He underwent an
open conversion and repair. His intercostal arteries were
found to be supplying the ruptured aneurysmal sac. The
patient survived the procedure.
Open conversions. Five patients had open conver-
sions; all of them had originally received TAG devices for
aneurysmal disease. One of the patients, who had type I and
III endoleaks, has already been described; details of the
other 4 are provided below.
The delivery sheath perforated the aneurysm sac and
caused extensive hemorrhaging in one patient with a very
tortuous aorta and a 10-cm aneurysm extending distal to
the subclavian artery. A successful open conversion was
Table IV. Outcome of type II endoleaks in eight
patients
Indication
Intervention (outcome)
No Yes
Patients, No. 8
Descending thoracic aneurysms 5 (resolved)
Chronic dissection 1 (not resolved)
Withdrew from the study 2performed, but the patient died 2 weeks later of multiorgan
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rysm adjacent to the left subclavian artery was complicated
by severe arch angulation. The orientation of the graft and
severity of the endoleak required open conversion the day
after the initial procedure; the patient did well and had no
complications. In the other two patients, aneurysmal dila-
tion was seen proximal to the graft with involvement of the
arch vessels; an arch vessel transposition was performed
with antegrade delivery of TAG endograft with good re-
sults.
DISCUSSION
Despite recent advances in endovascular technology, en-
doleaks remain the Achilles heel of stent grafting and are a
complication not seen with open repair. Management and
treatment of endoleaks associatedwith endovascular interven-
tion for abdominal aortic aneurysms have been described, but
those after thoracic aortic stent grafting are less studied.2-11
Still, rates of endoleak after thoracic aortic stent grafting have
been thought to be lower than those in the abdominal aorta,
where 10% to 25% of patients are affected.12-19 In the Euro-
pean Collaborators on Stent-Graft Techniques for Thoracic
Aortic Aneurysm and Dissection Repair (EUROSTAR) and
United Kingdom Thoracic Endograft registries of thoracic
aortic stent grafting, endoleaks were relatively infrequent and
usually related to graft fixation (type I).18 Similar reports
indicate most endoleaks were seen early at junctional connec-
tions and proximal and distal sites.12,13 Our own results in a
previous series were comparable19; nevertheless, 15% of pa-
tients in the present study had endoleaks.
Most were type I distal endoleaks in patients with an
aortic dissection, and these were detected 30 days of the
procedure and resolved spontaneously. Such endoleaks
were the result of distal perfusion of the false lumen
through re-entry tears, and thrombosis of the false lumen at
the level of the stent sealed the leaks. Song et al,16 in their
published experience of endograft exclusion of both acute
and chronic descending thoracic aortic dissections, noted
thrombosis of the false lumen in 61% of patients at 30 days,
with 88% completely thrombosed at 12 months.16 These
results are similar to those of others.17,20 When endoleaks
develop30 days in patients with dissections, they may be
from reperfusion of the false lumen. In these patients, the
distal end of the graft is at risk of eroding through the
dissection flap, allowing flow into the false lumen.21 Pseu-
doaneurysm formation and the presence of symptoms are
the main causes of failure necessitating secondary interven-
tion.
Accurate placement in the arch can be very challenging,
and even a tiny distal migration during deployment of the
stent graft can result in inadequate proximal fixation; place-
ment of a proximal cuff or an additional endoluminal graft
can further complicate the repair.22 We suspect that a
curved, tortuous aortic arch resulted in an inadequate prox-
imal landing zone in three of our patients with thoracic
aneurysms who required reintervention for proximal en-
doleaks. Graft detachment and pressurization of the aneu-rysm sac have also been reported to cause proximal en-
doleak, but we did not see this complication in our study.14
Although relatively few reports of type II endoleaks
have been published, they comprised 21% of the endoleaks
in our study.12,18,23,24 The causes of type II endoleaks may
include the presence of small intercostal branches within
the excluded aneurysm sac or coverage of the left subclavian
artery.23,24 We saw only two type III endoleaks (1%).
Junctional endoleaks secondary to modular disconnection
or fabric disruption are not reported frequently,12 and the
newer generation of grafts feature a more aggressive over-
lapping design.13
CONCLUSION
The long-term consequences of endoleaks after en-
dografting in the thoracic aorta are somewhat unclear at
this time. Distal type I endoleaks in patients treated for
thoracic dissection are likely to resolve spontaneously and
may be monitored with CT scanning. When pseudoaneu-
rysm formation occurs or the patient becomes symptom-
atic, reintervention is indicated.
A distal type I endoleak that develops in a patient with
an aneurysm should be treated with an additional graft
when the endoleak is discovered. Open conversion with
visceral debranching may be necessary if the additional
stent grafts don’t resolve the endoleak, there is expansion of
the sac and the patient is symptomatic. We also recommend
aggressive treatment of proximal type I endoleaks with an
additional cuff or stent graft. Adequate landing zones are
necessary and subclavian–carotid bypass may also be indi-
cated. When the left subclavian artery is covered, coiling
should be considered to prevent retrograde endoleak. Aor-
tic arch debranching should be performed if all the above
fail, the sac is expanding and/or the patient is symptomatic.
Type II endoleak may be monitored with serial CT
scans unless the dimension of the aneurysm sac changes
significantly. Additional treatment may include ballooning
with coil embolization between the aortic endograft and
the sac. CT-guided coil embolization may be helpful in
Table V. Recommendations for different types of
endoleaks associated with endovascular repair of
descending thoracic aortic diseases
● Proximal type I: aggressive treatment with additional stent/cuff
With or without carotid–subclavian bypass or transposition
Coverage of left subclavian: coiling
Open conversion only if all the above fail, expansion
of the aneurysm sac and patient symptomatic
● Distal type I: additional cuff/stent (descending thoracic aneu-
rysms)
Pseudoaneurysm formation and/or symptomatic patient: ad-
ditional cuff/stent
Open conversion only if all the above fail, expansion
of the aneurysm sac and patient symptomatic
● Distal type I: watch and wait (thoracic aortic dissection)
● Type II: follow-up (balloon, coiling, guided by computed to-
mography scan, if needed)
● Type III: additional graftsuch cases.
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time of discovery to prevent increases in the aneurysm sac
size. In some cases, deployment and adequate ballooning
of an additional endoluminal graft to reline the existing
stent graft may ensure complete apposition of the graft to
the vessel wall (Table V).
Endoleaks represent a significant complication after
endovascular treatment of the thoracic aorta. More data are
needed to determine the risk of endoleak over time, and
long-term CT surveillance of patients with endografts re-
mains extremely important.
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